TRCT
ZBIO

Tower Research Capital (TRC)’s Zenas BioPharma ZBIO Stock Holding History

Tower Research Capital (TRC)’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$141K Buy
7,235
+6,440
+810% +$145K ﹤0.01% 1905
2025
Q4 		$28.9K Sell
795
-593
-43% -$19.5K ﹤0.01% 2828
2025
Q3 		$30.8K Sell
1,388
-1,158
-45% -$18.9K ﹤0.01% 2912
2025
Q2 		$24.7K Buy
2,546
+1,135
+80% +$11.1K ﹤0.01% 3555
2025
Q1 		$11.1K Buy
1,411
+294
+26% +$2.3K ﹤0.01% 3567
2024
Q4 		$9.15K Buy
+1,117
New +$17.4K ﹤0.01% 3934

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return

Tower Research Capital (TRC)'s ZBIO Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Zenas BioPharma (ZBIO) stake by 810% in Q1 2026, buying an estimated $145K and bringing the position to 7,235 shares worth $141K. The position accounts for ﹤0.01% of the portfolio, ranked #1905.

Tower Research Capital (TRC) first reported a position in ZBIO in Q4 2024 and has held it in 6 quarters since. 139 funds tracked by Wall St. Rank hold ZBIO as of Q1 2026.

  • Tower Research Capital (TRC) held 7,235 shares of Zenas BioPharma worth $141K as of Q1 2026.
  • Tower Research Capital (TRC) bought 6,440 Zenas BioPharma shares in Q1 2026, an estimated $145K.
  • Zenas BioPharma made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #1905 holding.
  • Tower Research Capital (TRC) first reported a position in Zenas BioPharma in Q4 2024 and has held it in 6 quarters since.
  • 139 funds tracked by Wall St. Rank held Zenas BioPharma as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.